Helder Cardoso

Helder Cardoso

Auto-generated profile, based on publicly available information

Helder Cardoso

Gastroenterology Department, Faculty of Medicine, University of Porto, Porto, Portugal; Gastroenterology Department, Hospitalar Center of São João, Porto, Portugal

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
HCHelder Cardoso
Helder Cardoso
AVAna Maria Vale
Ana Maria Vale
SRSusana Rodrigues
Susana Rodrigues
RGRegina Gonçalves
Regina Gonçalves
AAAndreia Albuquerque
Andreia Albuquerque
Guilherme MacedoGuilherme Macedo
Guilherme Macedo

1 September 2016 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
HCHelder Cardoso
Helder Cardoso
AAAna Margarida Alves
Ana Margarida Alves
MMMargarida Marques
Margarida Marques
AVAna Maria Vale
Ana Maria Vale
PPPedro Pereira
Pedro Pereira
Guilherme MacedoGuilherme Macedo
Guilherme Macedo
Sorafenib chemotherapy is the first-line therapy for patients with hepatocellular carcinoma (HCC) in an advanced stage. The aim of this study was to evaluate prognostic factors of survival in HCC patients treated with sorafenib, in real-life clinical practice. Retrospective study of HCC patients who initiated treatment with sorafenib, following assessment and indication from the multidisciplinary group. There were included 36 patients, mostly male (89%) and with a mean age of 65 years. The main etiologies were chronic hepatitis C (44%) and alcoholic liver disease (36%). Twenty patients (56%) were classified as Child-Pugh A and 16 patients (44%) as Child-Pugh B. Half of the patients group were staged as BCLC C and the remaining as BCLC B. Significant adverse events were observed in 15 patients (42%) and were associated with longer survival (21.5 vs. 3.2 months, p < 0.001). The most frequent adverse events were diarrhea and palmar-plantar syndrome. Median survival was 17.3 months for Child-Pugh A versus 3.2 months for Child-Pugh B patients (p = 0.001). Within Child-Pugh A, median OS was 21.5 months for BCLC B patients and 15.7 months for BCLC C patients (p = 0.001). The main prognostic factors beyond Child-Pugh class and BCLC stage included the occurrence of significant adverse events. Being related to increased time of exposure to the drug, it points out the need of dose reducing instead of discontinuation whenever significant adverse events occur.

17 January 2017 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
HCHelder Cardoso
Helder Cardoso
MSMarco Silva
Marco Silva
Qualidade de vida relacionada com a saúde · Hepatite C crónica · Antivíricos · Medições de resultados informados pelos doentes

1 September 2017 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
HCHélder Cardoso
Hélder Cardoso
MSMarco Silva
Marco Silva
FVFilipe Vilas-Boas
Filipe Vilas-Boas
RCRui Cunha
Rui Cunha
JLJoanne Lopes
Joanne Lopes
Guilherme MacedoGuilherme Macedo
Guilherme Macedo

1 May 2019 in Annals of Hepatology
Verified
Journal Article
Open access
FMFernando Mané
Fernando Mané
HCHélder Cardoso
Hélder Cardoso
RLRodrigo Liberal
Rodrigo Liberal
SLSusana Lopes
Susana Lopes
PPPedro Pereira
Pedro Pereira
Guilherme MacedoGuilherme Macedo
Guilherme Macedo
Primary biliary cholangitis is a rare disease with scarce epidemiological data in Southern Europe. The authors aimed to evaluate treatment response in a cohort of patients. This retrospective observational single-centre study included patients with diagnostic criteria of primary biliary cholangitis. Data on disease presentation, laboratory results, treatment and clinical endpoints were collected and analyzed. Fifty-three patients were included, 89% women, with mean age of 62±15 years at diagnosis. The majority was asymptomatic (49%), tested positive for antimitochondrial antibodies (96%) and had increased alkaline phosphatase (median=214U/L). 75% of the patients had liver histology and the majority were in Ludwig's stage I (42%). Autoimmune hepatitis (AIH) features were found in seven patients (13%). All were treated with ursodeoxycholic acid (UDCA) and 56% achieved biochemical response at one year; patients with AIH features exhibited steeper decreases in alkaline phosphatase (p=0.007) and reached the endpoint of 40% decrease in alkaline phosphatase more frequently (p=0.017). In conclusion a significant proportion of patients failed to achieve an adequate response to UDCA treatment. The response rate of patients with AIH features was better, which could be related to a different phenotype or to the potential impact of immunosuppressive agents.